Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M38,296Revenue $M15,259Net Margin (%)11.0Z-Score3.2
Enterprise Value $M44,385EPS $3.7Operating Margin %15.7F-Score5
P/E(ttm))20.7Cash Flow Per Share $5.6Pre-tax Margin (%)14.6Higher ROA y-yN
Price/Book4.610-y EBITDA Growth Rate %12.1Quick Ratio1.0Cash flow > EarningsY
Price/Sales2.35-y EBITDA Growth Rate %6.5Current Ratio1.6Lower Leverage y-yY
Price/Cash Flow11.7y-y EBITDA Growth Rate %3.4ROA % (ttm)7.3Higher Current Ratio y-yN
Dividend Yield %2.9Insider Buy (3m)0ROE % (ttm)22.3Less Shares Outstanding y-yY
Payout Ratio %60.0Shares Outstanding M542ROI % (ttm)15.1Gross Margin Increase y-yN

Gurus Latest Trades with BAX

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BAXDavid Dreman 2014-09-30 Buy 0.02%$71.28 - $77
($74.81)
$ 70.88-5%New holding, 3397 sh.3,397
BAXRay Dalio 2014-09-30 Add0.01%$71.28 - $77
($74.81)
$ 70.88-5%Add 220.37%18,463
BAXRobert Olstein 2014-09-30 Sold Out -0.59%$71.28 - $77
($74.81)
$ 70.88-5%Sold Out0
BAXJean-Marie Eveillard 2014-06-30 Add0.18%$71.98 - $75.45
($73.67)
$ 70.88-4%Add 90872.4%1,000,696
BAXJohn Keeley 2014-06-30 Buy 0.05%$71.98 - $75.45
($73.67)
$ 70.88-4%New holding, 37150 sh.37,150
BAXScott Black 2014-06-30 Reduce-0.43%$71.98 - $75.45
($73.67)
$ 70.88-4%Reduce -30.98%123,976
BAXVanguard Health Care Fund 2014-06-30 Sold Out -0.11%$71.98 - $75.45
($73.67)
$ 70.88-4%Sold Out0
BAXRay Dalio 2014-06-30 Reduce-0.03%$71.98 - $75.45
($73.67)
$ 70.88-4%Reduce -90.74%5,763
BAXJohn Hussman 2014-06-30 Reduce-0.02%$71.98 - $75.45
($73.67)
$ 70.88-4%Reduce -50%3,725
BAXDavid Dreman 2014-06-30 Sold Out -0.01%$71.98 - $75.45
($73.67)
$ 70.88-4%Sold Out0
BAXCharles Brandes 2014-03-31 Buy 0.19%$66.49 - $72.85
($68.75)
$ 70.883%New holding, 204560 sh.204,560
BAXScott Black 2014-03-31 Add0.17%$66.49 - $72.85
($68.75)
$ 70.883%Add 13.41%179,629
BAXDavid Dreman 2014-03-31 Buy 0.01%$66.49 - $72.85
($68.77)
$ 70.883%New holding, 2453 sh.2,453
BAXJean-Marie Eveillard 2014-03-31 Reduce$66.49 - $72.85
($68.77)
$ 70.883%Reduce -85.53%1,100
BAXChris Davis 2014-03-31 Sold Out $66.49 - $72.85
($68.77)
$ 70.883%Sold Out0
BAXJohn Hussman 2014-03-31 Reduce-0.49%$66.49 - $72.85
($68.75)
$ 70.883%Reduce -93.07%7,450
BAXVanguard Health Care Fund 2014-03-31 Reduce-0.41%$66.49 - $72.85
($68.75)
$ 70.883%Reduce -77.96%531,100
BAXRay Dalio 2014-03-31 Reduce-0.07%$66.49 - $72.85
($68.77)
$ 70.883%Reduce -67%62,263
BAXScott Black 2013-12-31 Add1.06%$63.89 - $69.47
($66.75)
$ 70.886%Add 776.11%158,392
BAXRobert Olstein 2013-12-31 Add0.15%$63.89 - $69.47
($66.75)
$ 70.886%Add 24.19%77,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BAX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BAX David Dreman 2014-09-303,39700.02New Buy
BAX Ray Dalio 2014-09-3018,46300.01+220.37%
BAX John Keeley 2014-09-3040,6500.010.06+9.42%
BAX Charles Brandes 2014-09-30225,0230.040.21+7.2%
BAX John Rogers 2014-09-3063,0510.010.06+2.94%
BAX Scott Black 2014-09-30124,3460.021.3+0.3%
BAX Bill Nygren 2014-09-301,623,0000.30.75
BAX Dodge & Cox 2014-09-303,38200
BAX John Hussman 2014-09-303,72500.02
BAX Jean-Marie Eveillard 2014-09-30997,0560.180.18-0.36%
BAX Tweedy Browne 2014-09-302,581,2770.484.3-0.42%
BAX Mario Gabelli 2014-09-30224,9400.040.09-7.58%
BAX Robert Olstein 2014-09-30000Sold Out
BAX Meridian Funds 2013-06-308,60000.02
Premium Most recent portfolio changes are included for Premium Members only!


BAX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FORSYTH JOHN DDirector 2014-08-15Sell4,830$74.9-5.37view
Shapazian Carole JDirector 2014-07-25Sell1,645$76.98-7.92view
STALLKAMP THOMAS TDirector 2014-07-24Sell8,300$76.82-7.73view
HANTSON LUDWIGCorporate Vice President 2014-07-09Sell24,693$76-6.74view
STROUCKEN ALBERT P LDirector 2014-05-27Sell3,840$74.41-4.74view
Shapazian Carole JDirector 2014-05-02Sell5,680$75.28-5.84view
STROUCKEN ALBERT P LDirector 2014-04-24Buy696$67.524.98view
STORM KEES JDirector 2014-04-23Sell5,760$72.45-2.17view
Devitt Blake EDirector 2014-04-21Sell4,334$73.12-3.06view
Bufalino Sebastian JCorporate Vice President 2014-03-27Sell21,600$75.1-5.62view

Press Releases about BAX :

    Quarterly/Annual Reports about BAX:

    News about BAX:

    Articles On GuruFocus.com
    Expectations, Price, and Fundamentals (Or Congressional Questions Gone Awry) Jan 23 2015 
    Pfizer Spreading Its Wings Into A New Domain Of Life Sciences Dec 09 2014 
    I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
    Becton, Dickinson and Co. (BDX) Dividend Stock Analysis Nov 19 2014 
    Medtronic Inc. (MDT) Dividend Stock Analysis Sep 12 2014 
    Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
    Abbott: A Brighter Future Aug 28 2014 
    Diamond Hill Capital Comments on Baxter International Inc Jul 25 2014 
    Why I Bought Baxter International Jun 19 2014 
    Becton, Dickinson and Co. (BDX) Dividend Stock Analysis May 30 2014 

    More From Other Websites
    Pfizer's Prevenar 13 Wins CHMP Backing for Expanded Use - Analyst Blog Jan 26 2015
    CareFusion Banks on Pipeline Strength, Pricing Woes Remain - Analyst Blog Jan 26 2015
    Merrimack Reveals Additional Data from Oncology Candidate - Analyst Blog Jan 22 2015
    Baxter's (BAX) PHOXILLUM Solutions Get FDA Nod for CRRT - Analyst Blog Jan 21 2015
    Baxter Receives FDA Approval for PHOXILLUM Solution for Electrolyte Management During Continuous... Jan 20 2015
    Baxter Receives FDA Approval for PHOXILLUM Solution for Electrolyte Management During Continuous... Jan 20 2015
    Merrimack Pharmaceuticals Presents Additional Analyses of Phase 3 MM-398 NAPOLI-1 Study at the... Jan 20 2015
    PharmaEngine Announces Expanded Analyses of Phase 3 MM-398 NAPOLI-1 Study Presented at the 2015 ASCO... Jan 19 2015
    Baxter Offers Yield In Hot Medical Products Group Jan 16 2015
    Saline Solution Shortages Drove Non-Sterile Intravenous Fluid Debacle Jan 15 2015
    Palmetto Health in Columbia, South Carolina, Receives Prestigious $100,000 Foster G. McGaw Prize for... Jan 15 2015
    NxStage Revises Up 2014 Guidance on Strong Home Growth - Analyst Blog Jan 14 2015
    BAXTER INTERNATIONAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jan 09 2015
    Blue Chips For A New Year Jan 07 2015
    Pfizer continues vaccine push, buys Switzerland's Redvax Jan 05 2015
    Baxter Submits Application for U.S. FDA Approval of BAX111, Investigational Recombinant Treatment... Dec 22 2014
    Baxter Submits Application for U.S. FDA Approval of BAX111, Investigational Recombinant Treatment... Dec 22 2014
    Baxter Submits Application for U.S. FDA Approval of BAX111, Investigational Recombinant Treatment... Dec 22 2014
    Baxter to Present at 33rd Annual J.P. Morgan Healthcare Conference Dec 18 2014
    Baxter to Present at 33rd Annual J.P. Morgan Healthcare Conference Dec 18 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Sww
    ReplySww - 6 months ago
    Bax medical devices revenue ~9b, bio science ~7b
    using 3X sales of medical devices company and 4X for drugs company, 27b+28b = 55b market cap,as of June 2014, BAX market cap is 39b, so it can sell for

    72 * (1 + 16/39) = 99

    72 is current stock price, with an upside of around 35%

    so my guess is BAX may be able to sell for around 90 after spin-off.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK